Forward-Looking Statements

To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements.

Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities Commission. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it will have on IntelGenx's operations, the demand for its products, global supply chains and economic activity in general. IntelGenx assumes no obligation to update or revise any forward-looking statement.
## Company Snapshot
### SEC Registered

<table>
<thead>
<tr>
<th>IntelGenx Corp. Founded</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSX-V (IGX)(^1)</td>
<td>CDN $0.35</td>
</tr>
<tr>
<td>OTCQB (IGXT)(^1)</td>
<td>US $0.23</td>
</tr>
<tr>
<td>Market Capitalization(^1)</td>
<td>CDN $39M</td>
</tr>
<tr>
<td>Shares Issued(^1)</td>
<td>110.3M</td>
</tr>
<tr>
<td>Outstanding Warrants(^1)</td>
<td>30M</td>
</tr>
<tr>
<td>Insider Beneficial Ownership(^1)</td>
<td>9%</td>
</tr>
<tr>
<td>Cash/Short Term Investments(^2)</td>
<td>US $4.4M</td>
</tr>
</tbody>
</table>

### Analyst Coverage

<table>
<thead>
<tr>
<th>Firm</th>
<th>Analyst</th>
</tr>
</thead>
<tbody>
<tr>
<td>Echelon Wealth Partner</td>
<td>Douglas Loe</td>
</tr>
<tr>
<td>H.C. Wainwright</td>
<td>Raghuram Selvaraju</td>
</tr>
<tr>
<td>First Berlin</td>
<td>Christian Orquera</td>
</tr>
</tbody>
</table>

1) As at June 1, 2020
2) As at March 31, 2020
IntelGenx’s Superior Film Technologies
Creating Next Generation Pharmaceutical Products

**Oral Films**
- Rapidly disintegrating oral films easing drug administration without the need for water

**Transmucosal Films**
- Buccal or sublingual films improving absorption, accelerating onset of action, and reducing side effects

**Oral Topical Films**
- Local topical films for extended release of mucoadhesive drug particles in the oral cavity

**Transdermal Patches**
- Prolonged duration of action while reducing the frequency of dosing and reducing adverse effects
Oral Film Formulations Offer Tangible Medical Benefits
Thin Oral Films as a Better Alternative to Conventional Dosage Forms

We are focused on areas where oral films are particularly well suited:

- Reduced side effects
- Improved bioavailability
- Enhanced efficacy
- Response time versus existing drugs
- Convenience

- Especially useful for patients with difficulty in swallowing or chewing solid dosage forms, e.g. the elderly and children
Portfolio with Near-Term Revenue Projections & High Potential Candidates

IntelGenx is preparing its first launch and investing into PoC Alzheimer’s Opportunity

**Cannabis VersaFilm®**
- Micro-Processing license obtained; launch date TBA

**Montelukast VersaFilm®**
- H2 2021 target for Phase Ila read-out
Cannabis VersaFilm® Will Set the Standard for Edible Films
Ease of Use, Avoidance of Swallowing and Pleasant Taste are Key Drivers of Appeal

Source: *Among the 76% who found it appealing, Market Research by the Logit Group 08/2018,
Cannabis-Infused VersaFilm®: a Winning Partnership with Tilray™

IntelGenx is Well Positioned to Capitalize on the Global Cannabis Opportunity

- $5BN projected cannabis market in Canada*
- Focus on fast ramp up for commercial production
- Consistent supply and global reach through Tilray partnership
- Differentiated product due to unique dose delivery

Source: *Financial Post 02/2019
Strong Growth Expectations for “Adult only” Brand in Canada
IntelGenx’s Cannabis VersaFilm® will be Positioned as a Differentiated Premium Brand

- Differentiated through novel film delivery
- Quality assurance
- Premium consumer brand approach
- Analytically-driven operations
- (Child-resistant packaging certification)

Revenue (CAD MM)

<table>
<thead>
<tr>
<th>Year</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4</td>
<td>7</td>
<td>8.4</td>
<td>9</td>
<td>10.4</td>
</tr>
</tbody>
</table>

IntelGenx estimated manufacturing revenues\(^1\) based on Canadian sales (2020-2024) of one film product.

1) Under the existing agreement with Tilray, the company is additionally entitled to a royalty on Tilray’s net sales. The partner intends to commercialize multiple products.
Follow-on Projects for Cannabis-Infused VersaFilm® Will Target Medicinal Use
Ongoing innovation for global reach for Medical Purposes

Potential medical indications for use of Cannabidiol (CBD)

Some indications require the combination of CBD and THC

- treatment and reduction of seizures
- relief of symptoms related to multiple sclerosis
- involuntary muscle contractions (dystonia)
- psychosis associated with Parkinson disease
- schizophrenia
- anxiety disorders
- neuropathic and chronic pain
- opioid drug withdrawal

For Medical Purposes

| SPEND PER YEAR | $1,476 |
| INCIDENCE     | 12%    |
| LEGAL AGE POPULATION* | 26,469,251 |
| ANNUAL SPEND  | $4,688,233,770 |

Source: *Statistics Canada, based on a total Canadian population of 35,151,728
IntelGenx is preparing first product launch and investing into PoC Alzheimer’s opportunity

- Micro-Processing license obtained; launch date TBA
- H2 2021 target for Phase Ila read-out
Mild-to-Moderate Alzheimer's Disease
Sizeable Addressable Patient Population and Market Opportunity

- Currently approved treatments for brain degenerative diseases are limited
- Unmet clinical needs
- Wide open market opportunity

Cognitive Disorder Stage and Prevalent Population in 9 Different Markets
(Global Data, 2013)

- Mild Cognitive Impairment (MCI) > 80 Mi persons
- Alzheimer’s Disease (AD)
  1. Mild > 6.5 Mi persons
  2. Moderate > 3.9 Mi persons
  3. Severe > 2.1 Mi persons
- Dementia > 30 Mi persons

Global Sales for AD by Patients Category
(Global Data, 2013)

- 2013 Total: $4.9bn
- 2023 Total: $13.3bn

- MCI 57%
- Mild 15%
- Moderate 12%
- Severe 5%
- Other 6%
Montelukast for Mild-to-Moderate Alzheimer's Disease

Major Repurposing Opportunity with Tangible Benefits

- Montelukast is a leukotriene receptor antagonist
- Potential to reduce neuroinflammation and restore brain cell function
- Possibility of Montelukast as the first disease modifying treatment for Alzheimer’s Disease (AD)

Already Approved and Established Drug

Strong Preclinical Evidence

Supporting Epidemiology Data

Supporting Ph1 Data

IP Strategy

- Improved bioavailability
- Demonstrated ability to cross blood-brain barrier
- Overcomes compliance issue in elderly Alzheimer’s Disease patients
Improves Cognitive Functions & Structural Integrity of the Brain

Preclinical Demonstration

- Improves Learning and Memory in aged animals
- Crosses the Blood-Brain Barrier in rats and humans
- Restores Blood Vessel Structural Integrity
- Returns Generation of New Neurons
- Restores Learning and Memory in a Model of Lewy Body dementia
- Improves function in a number of models of acute and chronic neurodegenerative diseases

Early Clinical Evidence

Before:
MMSE 13: moderate to severe dementia

After 2 Months:
MMSE 22: Mild Dementia

Note: MMSE = Mini-Mental State Examination; is a test to measure cognitive impairment
Phase I Clinical Study Completed
Positive Results

A Single-Dose, Non-Randomized, Open-Label, Two-Way, Pilot, Comparative Bioavailability Study of Montelukast 10 mg Oral Film (IntelGenx Corp.) and Singulair® 10 mg Film-coated Tablet (Merck & Co., Inc., approved for Asthma in 1998) in Healthy Male and Non-pregnant Female Volunteers under Fasting Conditions

Montelukast Mean Plasma Profile

CSF level measured for Buccal Film (average of 8)

<table>
<thead>
<tr>
<th>CSF</th>
<th>ng/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average at 3 hours</td>
<td>3.6</td>
</tr>
<tr>
<td>Average at 7 hours</td>
<td>4.2</td>
</tr>
</tbody>
</table>

Safety Results:
A total of 2 possibly related adverse events to the buccal film were reported. A total of 2 subjects experienced somnolence when taking the buccal film.
Proof of Concept Phase IIa Clinical Study

Underway

“A randomized Phase IIa, multi-center, double-blind, placebo-controlled study to assess the safety, feasibility, tolerability, and efficacy of a new buccal film of Montelukast in patients with mild to moderate Alzheimer’s Disease”

- Study protocol approved by Health Canada
- Only known cysLT-1 receptor antagonist clinical study in patients with Alzheimer’s Disease
- Study Drug: Montelukast VersaFilm® buccal film and matching placebo
- Treatment duration for each patient: 26 weeks
- Assessment of the treatment effect: cognitive abilities and exploratory biomarkers
- Number of patients: 70 (35 per arm; montelukast versus placebo)
- Patients: ≥50 years of age with mild to moderate Alzheimer’s Disease and treated daily with donepezil, rivastigmine or galantamine for ≥3 months
- 8 Canadian sites and 1 oncoming U.S site; retained services of contract research organizations Cogstate and JSS Medical Research
- Patient screening and enrolment commenced Q3-2018; 26 subjects randomized as of August 22, 2019
- Independent Data Safety Monitoring Board (“DSMB”) completed its first interim analysis in October 2019
- Received Health Canada approval to increase dosage to 2X30mg daily vs 10mg daily in January 2020
- New patient enrollment on temporary hold due to COVID-19
Additional Oral Film Opportunities to be Launched in the U.S.
Other exciting upcoming launches over the next 3 years

- **Rizaport®**  
  • Target date TBA

- **Exordia®**  
  • 2021 target for launch
Rizaport® & Exordia®: Additional Near-Term Product Launches
Tackling Large Market Opportunities Adding to Top Line Revenue

RIZAPORT® for Migraines

- Anticipated 1st year sales > $30Mio
- Commercial partnership with Gensco Pharma in U.S.
- FDA CRL received March 27, 2020; resubmitted NDA in Q3 2019; Type A meeting with FDA took place on June 10, 2020; completing the work required to resubmit the RIZAPORT® VersaFilm® NDA
- Additional commercial partners for Spain and South Korea

Exordia® for Erectile Dysfunction

- U.S. ED market at $2.95 BN and forecast to grow at 6.5% by 2023*
- Commercial partnership with Aquestive Therapeutics
  - Collaboration on CRL response and resubmission
  - Additional territories under evaluation

Source: *MarketWatch 02/2019
## Mature Product Pipeline
### Addressing Significant Market Opportunities

<table>
<thead>
<tr>
<th>Indication</th>
<th>Partnering Status</th>
<th>Formulation Development</th>
<th>Clinical</th>
<th>Filing</th>
<th>Launch</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cannabis Products</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adult-Use and Medical (Cannabinoids)</td>
<td>Partnered</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TILRAY Logo</td>
</tr>
<tr>
<td><strong>Pain</strong> (Dronabinol)</td>
<td>Available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Tetra Logo</td>
</tr>
<tr>
<td><strong>Neurodegenerative Brain Diseases</strong> (Montelukast)</td>
<td>Available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Exeltis Logo</td>
</tr>
<tr>
<td><strong>Migraine – RIZAPORT®</strong> (Rizatriptan)</td>
<td>Available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aquestive Logo</td>
</tr>
<tr>
<td><strong>Erectile Dysfunction - Exordia®</strong> (Tadalafil)</td>
<td>Partnered</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Piper Logo</td>
</tr>
<tr>
<td><strong>Opioid Dependence</strong> (Buprenorphine/ Naloxone)</td>
<td>Partnered</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Insud Pharma Logo</td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td>Partnered</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Schizophrenia</strong> (Loxapine)</td>
<td>Available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Endo Logo</td>
</tr>
<tr>
<td><strong>Undisclosed</strong></td>
<td>Partnered</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Undisclosed</strong></td>
<td>Partnered</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Undisclosed</strong></td>
<td>Partnered</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Low Risk Targeted Business Model
Established Strategic Partnerships

• Commercial deals are usually structured such that partners are granted exclusive rights to market and sell products in exchange for potential **upfront and milestone** payments, together with a share of partner’s **net profits** or a **royalty** on net sales.

• IntelGenx **retains manufacturing rights** for its film products.

• Payments would be received as the contracted **services are performed** or when certain agreed-upon **milestones are achieved**:
  - FDA submission  - FDA approval
  - Commercial launch  - Annual net sales target, etc.

• **Partners pay** for part or all of the **R&D expenses** associated with product development and obtaining regulatory approval.

• IntelGenx may also receive **R&D tax credits** for product development.
Full-Service Capabilities
Validation of Strategic Shift

• Agreements with commercialization partners (e.g. Gensco® Pharma, ENDO, Aquestive and Tilray®) validate IntelGenx’s strategic shift from an exclusively R&D company (dependent on royalty and license revenues) to a full-service company

• Our added manufacturing ability represents a profitable business opportunity; 17,000 sq. ft. facility in Montreal fully GMP compliant

• Health Canada certified – Drug Establishment License (DEL) since 2017

• Customized manufacturing equipment

• Health Canada approved dealer’s license for controlled substances
Accelerated Focus on Short-Term Revenue Generating Opportunities
Pursuing Additional Products Without FDA or HC Approval Requirement

**Hand Sanitizers**
- Health Canada recently authorized sale of IntelGenx’s hand sanitizer product, both in liquid and gel formulations

**Cannabis Infused VersaFilm®**
- Commercial launch plans announcement pending

**Nutraceutical Films**
- Already in active discussions with potential partners
## Accomplished Leadership Team

>40 Employees

<table>
<thead>
<tr>
<th>Member</th>
<th>Position</th>
<th>Experience and Achievements</th>
</tr>
</thead>
</table>
| Horst G. Zerbe, Ph.D. | Chairman & CEO | • Co-inventor of Listerine oral strips  
• 30+ years drug delivery / pharma experience (Lohmann Therapy Systems, 3M Pharmaceuticals, Smartrix Technologies)  
• Pioneer in development and manufacturing of oral films and transdermal products  
• Numerous patents and scientific publications |
| Andre Godin, CPA, CA | President & CFO | • 25+ years biotech/pharma industry experience  
• Member of the Canadian Chartered Professional Accountants and the Canadian Institute of Chartered Accountants |
| Nadine Paiement, M. Sc. | VP, Research & Development | • Co-inventor of IntelGenx Trilayer Technology  
• 15 years experience in product development and technology transfer |
| Dana Matzen, Ph.D. | VP, Business & Corporate Development | • 15 years experience in pharmaceutical product licensing  
• Prev. Director, BD at Paladin  
• Completed 13 transactions, 7 new product launches |
| Rodolphe Obeid, Ph.D. | VP, Operations | • 5+ years experience in manufacturing & scale-up of oral film products  
• Author and co-author of numerous scientific papers, patents, book chapters, and scientific communications |
| Ana Maria Hannah, Ph.D. | Sr. Dir., Quality Operations | • 4+ years experience in regulatory affairs and quality operations  
• Coordinated multiple renewals and registrations in RoW regions |
Thank You!
Contact Information

Stephen Kilmer
Investor Relations
+1-514-331-7440 ext. 232
Stephen@intelgenx.com

André Godin
President & CFO
+1-514-331-7440 ext. 203
Andre@intelgenx.com

Dana Matzen, Ph.D.
VP Corp & BD
+1-514-331-7440 ext. 220
Dana@intelgenx.com

IntelGenx Corporate Offices
6420 Abrams
Saint-Laurent (Quebec)
H4S 1Y2 Canada
www.intelgenx.com